The Infanrix Hexa Vaccine Kills 36 in Clinical Trials, 1700 injured
READ BEFORE ENTERING; This website is for information purposes only; This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of Top-life coach or its staff.
Hexavalent vaccines are now on the market. Vaxelis is a hexavalent vaccine. The prefix means six. It contains six different vaccines in one injection.
The HEXAVALENT Vaccines.
The FDA approved a new combination vaccine – Vaxelis is designed for toddlers ages six weeks to 4-years-old. Are they trying to put more shots into one to give a ruse of fewer vaccinations? It contains diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenza type B.
Multivalent vaccines have never been safety-tested by the FDA. Do some claim it is better to give more at once to reduce distress but is that safe? Probably not.
This study suggests that combining childhood vaccines in one visit is not safe.
A review of the Vaccine Adverse Event Reporting System (VAERS) shows a dose-dependent association between the number of vaccines administered simultaneously and the likelihood of hospitalization or death for an adverse reaction.
But it is so apparent now after researching day after day that there is little concern for safety, opposing opinions, conflicting evidence, or opposing science. The concern is the agenda and profits.
HEXA Vaccine – 36 children died, and more than 1700 were injured in a clinical trial for the Infanrix HEXA vaccine.
The Infanrix Hexa, six-in-one vaccine, killed 36 children in the clinical trial—and injured over one thousand. GlaxoSmithKline (GSK) is *supposed* to contain the following: tetanus, diphtheria, and pertussis toxoids; inactivated poliomyelitis viral strains 1-2-3; and hepatitis B surface antigen. Shockingly, Corvelva found none of these antigens in the vaccine. That means no antibodies to the intended antigens will be created.
According to the website Initiative Citoyenne [2] who reported the news, the 1271 page document revealed that GlaxoSmithKline received a total of 1,742 reports of adverse reactions between October 23, 2009, and October 22, 2011, including 503 serious adverse reactions and 36 deaths. Initiative Citoyenne stated:
“It’s not that 14 deaths were recorded by GSK between October 2009 and end in October 2011 as we had originally calculated but 36 (14 from 2010 to 2011 and 22 from 2009 to 2010). In addition to these 36 deaths at least 37 other deaths (sudden death mainly), bringing the total to at least 73 deaths since the launch of the vaccine in 2000, and again, this concerns only the death by sudden death, no further recovery of under-reporting.”
Confidential reports by GSK described fatal outcomes and adverse events from their trial. Here is a small part of the confidential report showing 77 cases of Gaze Palsy and more.
8.2. Cumulative review of Gaze palsy
In the assessment report (dated 3 March 2010) of PSUR 14, EMA had the following request:
b. During the period of this report, 14 cases of gaze palsy have been identified. In ten of the cases, the event was reported in association with concurrent events, mostly convulsions. However, the median TTO is less than one day. In addition, the outcome was reported resolved with sequelae in 1 case and unresolved in 1 case. The MAH is requested to provide a detailed cumulative reviewing of cases of Gaze palsy since launch. The events, TTO, outcome, and concomitant drugs should be specified. Accordingly, a cumulative review of cases of Gaze palsy diagnosed after Infanrix Hexa administration was performed. All spontaneous reports in the GSK worldwide safety database reported from Infanrix Hexa launch up to a data lock point of 22 October 2011 were included in the analysis.
Since launch, 70 spontaneous cases of Gaze Palsy were received, corresponding to a reporting frequency of 0.10 per 100 000 Infanrix hexa doses distributed. All cases are summarized in Appendix 2, including time to onset, events, outcome and concomitant drugs reported.
In 45/70 cases the event occurred on the same day of vaccination. In all cases, Gaze Palsy was one of the presenting symptoms of a larger clinical syndrome, i.e., Febrile and nonfebrile Convulsion and Hypotonic-hyporesponsive episode (HHE), which are both listed events in the Infanrix Hexa reference safety information. In 43 cases the outcome was reported to be ‘Resolved’ or ‘Resolved with sequelae’. In the other cases outcome was either ‘Improved’ (N=1), ‘Unresolved’ (N=6) or ‘Unknown
9. OVERALL SAFETY EVALUATION AND CONCLUSION
From the review of data received during the reporting period and presented in this report, it has been concluded that the safety profile of Infanrix hexa is adequately reflected in the RSI.
No further amendments to the RSI are considered necessary at this time. The benefit/risk profile of Infanrix hexa continues to be favourable.
Corvela Studied Infanrix and the results are mind-blowing
The link to the study has been removed. We cited the papers original information:
In Infanrix Hexa we found
- chemical contamination from the manufacturing process or cross-contamination with other manufacturing lines;
- chemical toxins;
- bacterial peptide toxins;
- insoluble and indigestible macromolecule that reacts to the protein assay, but cannot be recognized by any protein databases.
We have not found:
- Protein antigens of diphtheria toxoids, tetanus, pertussis, hepatitis B, haemophylus influenza B, Poliomyelitis 1-2-3;
- Formaldehyde and glutaraldehyde, phenoxyethanol, antibiotic residues indicated in the composition;
Since this polymer we have encountered, derived from the antigenic mix, is not only different for its spatial conformation but it’s chemically different, so we can state that we are not facing antigens similar to the original ones but in the form of a compound with an unknown and unpredictable toxicity and efficacy.
Not only vaccine antigens have been not detected, but there were also 65 signs of chemical contaminants of which only 35% is known, there are among these various processing residues and cross-contaminations from other manufacturing lines, and their identification will be checked during the second level of the analytical study (i.e. with standard controls).
7 chemical toxins among these signals have also been identified, probably deriving from chemical contaminants of the manufacturing process or other manufacturing lines at the vaccine manufacturing site; these toxins have a structure that could probably be partially derived from the formaldehyde, glutaraldehyde, and cyanogen bromide reaction with other chemical contaminants in the vaccine. We’d like to point out that the toxicity of many of these toxins have been confirmed and published in Pubchem or Toxnet and this poses important safety problems, issues and concerns.
https://www.corvelva.it/it/speciali-corvelva/analisi/vaccingate-initial-results-on-infanrix-hexa-chemical-composition.html
|
VAERS ID |
|
||||||
|---|---|---|---|---|---|---|---|---|
| DEATH | Within hours of vaccination (night of vaccination day) infant became febrile. At approximately 2:00AM on 1/26/2012, he was taken to hospital because of breathing difficulty. Infant was resuscitated at hospital but expired on 1/27/2012. | |||||||
| This spontaneous report was received from a physician, via a company representative, referring to four female patients of unknown age. The patients’ pertinent medical history, concurrent conditions, drug reactions/allergies and concomitant medications were not provided. On unknown dates, the patients were vaccinated with diphtheria toxoid (+) hepatitis b virus vaccine rhbsag (yeast) (+) hib conj vaccine (ompc) (+) pertussis acellular 5-component vaccine (+) poliovirus vaccine inactivated (vero) (+) tetanus toxoid (manufacturer unknown) for prophylaxis (strength, dose, route, anatomical location, lot # and expiration date were not reported). On unknown dates, the patients died. It was unknown if an autopsy was performed. The causality assessment was not provided.; Sender’s Comments: US-009507513-1905USA004181: US-009507513-1905USA004180: US-009507513-1905USA004179: US-009507513-1905USA004178: US-009507513-1905USA004182: US-009507513-1904USA013391: | ||||||||
| This spontaneous report was received from a physician, via a company representative, referring to six male patients of unknown age. The patients’ pertinent medical history, concurrent conditions, drug reactions/allergies and concomitant medications were not provided. On unknown dates, the patients were vaccinated with diphtheria toxoid (+) hepatitis b virus vaccine rhbsag (yeast) (+) hib conj vaccine (ompc) (+) pertussis acellular 5-component vaccine (+) poliovirus vaccine inactivated (vero) (+) tetanus toxoid (manufacturer unknown) for prophylaxis (strength, dose, route, anatomical location, lot # and expiration date were not reported). On unknown dates, the patients died. It was unknown if an autopsy was performed. The causality assessment was not provided. ; Sender’s Comments: US-009507513-1905USA004181: US-009507513-1905USA004180: US-009507513-1905USA004179: US-009507513-1904USA013391: US-009507513-1905USA004182: US-009507513-1905USA004177: |
This website is for information purposes only; we are not diagnosing, treating, curing, mitigating, or preventing any disease or medical condition by providing the information contained herein. Before beginning any natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.
